Видео ютуба по тегу Sara Hurvitz

Dr. Sara Hurvitz | San Antonio Breast Cancer Symposium 2022 | General Session
Dr. Sara Hurvitz | San Antonio Breast Cancer Symposium 2022 | General Session
Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer
Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer
Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin
Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin
Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials
Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials
Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research
Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research
Dr. Sara Hurvitz invites you the International Congress on the Future of Breast Cancer West
Dr. Sara Hurvitz invites you the International Congress on the Future of Breast Cancer West
Dr. Sara Hurvitz Discusses the Latest Developments in Breast Cancer Research
Dr. Sara Hurvitz Discusses the Latest Developments in Breast Cancer Research
Dr. Hurvitz on the FDA Approval Process for Biosimilars
Dr. Hurvitz on the FDA Approval Process for Biosimilars
Dr. Hurvitz on the Future of the Treatment of TNBC
Dr. Hurvitz on the Future of the Treatment of TNBC
T-DM1 may extend PFS among patients with unresectable locally advanced or metastatic HER2-positi...
T-DM1 may extend PFS among patients with unresectable locally advanced or metastatic HER2-positi...
Dr. Hurvitz on Treatment Hypotheses for TNBC
Dr. Hurvitz on Treatment Hypotheses for TNBC
Patient Success Stories: Metastatic ER+ Breast Cancer, Sara Hurvitz MD
Patient Success Stories: Metastatic ER+ Breast Cancer, Sara Hurvitz MD
Dr. Hurvitz on Biosimilars in Breast Cancer
Dr. Hurvitz on Biosimilars in Breast Cancer
Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast Cancer
Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast Cancer
Dr. Hurvitz on Pembrolizumab for TNBC
Dr. Hurvitz on Pembrolizumab for TNBC
Dr. Hurvitz on Patient Outcomes and PIK3CA Mutations
Dr. Hurvitz on Patient Outcomes and PIK3CA Mutations
Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer
Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer
Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast Cancer
Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast Cancer
Treatment Selection for HR+ mBC
Treatment Selection for HR+ mBC
Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment
Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment
Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer
Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer
Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer
Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer
Metastatic HR+ Breast Cancer: Developments and Approvals
Metastatic HR+ Breast Cancer: Developments and Approvals
A discussion with Dr. Sara Hurvitz, San Antonio Breast Cancer Symposium 2010.
A discussion with Dr. Sara Hurvitz, San Antonio Breast Cancer Symposium 2010.
Introduction and Exploration of Fulvestrant in Metastatic Breast Cancer
Introduction and Exploration of Fulvestrant in Metastatic Breast Cancer